{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:16:15Z","timestamp":1758845775464,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Chromogenic in situ hybridisation (CISH) is an alternative to immunohistochemistry or FISH for the assessment of HER2 oncogene status in breast cancer. Although CISH is being used increasingly in routine diagnostics, there are no established inter-laboratory quality assurance programmes for this test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>The reproducibility of HER2 CISH analysis was assessed when performed by seven different centres that use the test routinely in diagnostic service.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>The results from 28 cases showed overall concordance of 98.5% (192\/195 tests; \u03ba coefficient 0.91). One of the discrepancies was due to the invasive carcinoma having been cut out in the sections received by two of the centres, and the other two were in the non-amplified\/equivocal\/low-amplified category.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>This is believed to be the first report of a quality assurance study assessing laboratories that use HER2 CISH routinely in clinical diagnostics. The results show that CISH is a robust technique providing a suitable assay for the frontline testing of HER2 status in breast cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jcp.2007.053850","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T20:45:05Z","timestamp":1204836305000},"page":"757-760","source":"Crossref","is-referenced-by-count":19,"title":["A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer"],"prefix":"10.1136","volume":"61","author":[{"given":"S","family":"Di Palma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bilous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Sapino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mottolese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kapranos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Isola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2008,3,6]]},"reference":[{"key":"2025092504151979000_61.6.757.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"2025092504151979000_61.6.757.2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880440"},{"key":"2025092504151979000_61.6.757.3","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.2001.19.10.2714","article-title":"Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.","volume":"19","author":"Tubbs","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025092504151979000_61.6.757.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2002.01327.x"},{"key":"2025092504151979000_61.6.757.5","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.1999.17.7.1983","article-title":"Specificity of HercepTest in determining HER-2\/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.","volume":"17","author":"Jacobs","year":"1999","journal-title":"J Clin Oncol"},{"key":"2025092504151979000_61.6.757.6","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.040840"},{"key":"2025092504151979000_61.6.757.7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm075"},{"key":"2025092504151979000_61.6.757.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2005.09.008"},{"key":"2025092504151979000_61.6.757.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-8-878"},{"key":"2025092504151979000_61.6.757.10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800432"},{"key":"2025092504151979000_61.6.757.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0428-03"},{"key":"2025092504151979000_61.6.757.12","doi-asserted-by":"publisher","DOI":"10.1309\/C4PE-BGB9-LN83-0TVL"},{"key":"2025092504151979000_61.6.757.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-004-2186-6"},{"key":"2025092504151979000_61.6.757.14","doi-asserted-by":"crossref","unstructured":"Arnould L Denoux Y MacGrogan G . Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003 19;88:1587\u201391.","DOI":"10.1038\/sj.bjc.6600943"},{"key":"2025092504151979000_61.6.757.15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/01.LAB.0000024360.48464.A4","article-title":"Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.","volume":"82","author":"Dandachi","year":"2002","journal-title":"Lab Invest"},{"key":"2025092504151979000_61.6.757.16","doi-asserted-by":"publisher","DOI":"10.1080\/00313020600561518"},{"key":"2025092504151979000_61.6.757.17","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800555"},{"key":"2025092504151979000_61.6.757.18","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1776"},{"key":"2025092504151979000_61.6.757.19","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.043356"},{"key":"2025092504151979000_61.6.757.20","doi-asserted-by":"crossref","unstructured":"Joensuu H Kellokumpu-Lehtinen PL Bono P . Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809\u201320.","DOI":"10.1056\/NEJMoa053028"},{"key":"2025092504151979000_61.6.757.21","doi-asserted-by":"publisher","DOI":"10.1080\/00313020120083133"},{"key":"2025092504151979000_61.6.757.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000052102.90815.82"},{"key":"2025092504151979000_61.6.757.23","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.007724"},{"key":"2025092504151979000_61.6.757.24","doi-asserted-by":"publisher","DOI":"10.1037\/h0031619"},{"key":"2025092504151979000_61.6.757.25","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"2025092504151979000_61.6.757.26","doi-asserted-by":"crossref","unstructured":"Paik S Kim C Jeong J . Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and\/or FISH-positive tumors: central testing results from NSABP B-31. Proceedings of the American Society of Clinical Oncology Annual Meeting; 1\u20135 June 2007, Chicago. Chicago: American Society of Clinical Oncology, 2007, abstract no 511.","DOI":"10.1200\/jco.2007.25.18_suppl.511"},{"key":"2025092504151979000_61.6.757.27","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2005.n.026"},{"key":"2025092504151979000_61.6.757.28","unstructured":"Mass R Press M Anderson S . Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract]. Proc Am Soc Clin Oncol 2001;20:22a."},{"key":"2025092504151979000_61.6.757.29","doi-asserted-by":"crossref","unstructured":"Arnould L Arveux P Couturier J . Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Can Res 2007:6404\u20139.","DOI":"10.1158\/1078-0432.CCR-06-3022"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2007.053850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:15:32Z","timestamp":1758798932000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2007.053850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,5,27]]},"published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1136\/jcp.2007.053850"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2007.053850","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2008,3,6]]}}}